DTC Act of 2025

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 3789 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 3789 To amend title XI of the Social Security Act to require that direct-to- consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES June 5, 2025 Mr. Taylor (for himself and Ms. Schakowsky) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XI of the Social Security Act to require that direct-to- consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug-price Transparency for Consumers Act of 2025'' or the ``DTC Act of 2025''. SEC. 2. FINDINGS; SENSE OF THE SENATE. (a) Findings.--Congress finds the following: (1) Direct-to-consumer advertising of prescription pharmaceuticals is legally permitted in only 2 developed countries, the United States and New Zealand. (2) In 2018, pharmaceutical ad spending exceeded $6,046,000,000, a 4.8-percent increase over 2017, resulting in the average American seeing 9 drug advertisements per day. (3) The most commonly advertised medication in the United States in 2020 had a list price of more than $6,000 for a one- month supply. (4) A 2021 Government Accountability Office report found that two-thirds of all direct-to-con